Los Angeles Capital Management LLC purchased a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) in the 2nd quarter, HoldingsChannel reports. The firm purchased 32,755 shares of the company’s stock, valued at approximately $246,000.
Several other hedge funds have also recently added to or reduced their stakes in RXRX. Mubadala Investment Co PJSC bought a new position in Recursion Pharmaceuticals during the 4th quarter worth approximately $128,041,000. ARK Investment Management LLC increased its stake in shares of Recursion Pharmaceuticals by 14.5% in the 2nd quarter. ARK Investment Management LLC now owns 28,142,918 shares of the company’s stock valued at $211,072,000 after acquiring an additional 3,555,357 shares in the last quarter. Norges Bank bought a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at $34,825,000. Baillie Gifford & Co. increased its stake in shares of Recursion Pharmaceuticals by 10.5% in the 2nd quarter. Baillie Gifford & Co. now owns 26,589,936 shares of the company’s stock valued at $199,425,000 after acquiring an additional 2,522,132 shares in the last quarter. Finally, Kinnevik AB publ increased its stake in shares of Recursion Pharmaceuticals by 14.4% in the 2nd quarter. Kinnevik AB publ now owns 11,905,668 shares of the company’s stock valued at $89,293,000 after acquiring an additional 1,500,000 shares in the last quarter. Institutional investors own 89.06% of the company’s stock.
Insider Buying and Selling
In related news, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $9.51, for a total value of $108,860.97. Following the sale, the director now directly owns 7,177,116 shares in the company, valued at approximately $68,254,373.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Christopher Gibson sold 50,000 shares of the business’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $7.48, for a total value of $374,000.00. Following the sale, the chief executive officer now directly owns 758,738 shares in the company, valued at approximately $5,675,360.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $9.51, for a total value of $108,860.97. Following the completion of the sale, the director now owns 7,177,116 shares in the company, valued at $68,254,373.16. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 231,682 shares of company stock valued at $1,663,867. 15.75% of the stock is owned by insiders.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Analysis on Recursion Pharmaceuticals
Recursion Pharmaceuticals Price Performance
RXRX opened at $6.57 on Monday. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.04. The firm’s fifty day moving average price is $7.23 and its two-hundred day moving average price is $8.52. Recursion Pharmaceuticals, Inc. has a 1 year low of $4.97 and a 1 year high of $15.74.
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). The firm had revenue of $14.42 million for the quarter, compared to analysts’ expectations of $11.96 million. Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. Recursion Pharmaceuticals’s revenue was up 30.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.38) earnings per share. On average, equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current year.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Articles
- Five stocks we like better than Recursion Pharmaceuticals
- How to Choose Top Rated Stocks
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- The Role Economic Reports Play in a Successful Investment Strategy
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- How to Use the MarketBeat Dividend Calculator
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Want to see what other hedge funds are holding RXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report).
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.